News &amp; Updates

There appears to be no longitudinal association between hair cortisol and cortisone levels with dementia and various measures of cognitive function, a recent study has found.

Hair cortisol, cortisone unrelated to cognitive function, dementia

06 Dec 2022

Lecanemab moderately slows decline in early AD, associated with AEs

06 Dec 2022 by

Lecanemab reduces brain amyloid burden and offers moderate slowing of cognitive decline in early Alzheimer’s disease (AD), but is associated with adverse events (AEs), according to the results of the phase III, double-blind, placebo-controlled CLARITY AD trial, presented at the 15^th Clinical Trials on Alzheimer’s Disease (CTAD 2022) conference.

Lecanemab moderately slows decline in early AD, associated with AEs

06 Dec 2022

Transvaginal photobiomodulation helps resolve pelvic pain, dysuria

Most women with interstitial cystitis/bladder pain syndrome (IC/BPS) achieve a significant reduction in pelvic pain and dysuria following transvaginal photobiomodulation (TV-PBM), previously referred as low-level laser therapy, according to real-world data.

Transvaginal photobiomodulation helps resolve pelvic pain, dysuria

Midodrine a novel option for PICD prevention in ACLF

06 Dec 2022 by

Oral midodrine may be a good alternative to intravenous albumin for preventing paracentesis-induced circulatory dysfunction (PICD) in patients with acute-on-chronic liver failure (ACLF) undergoing modest-volume paracentesis for ascites, suggests a new study.

Midodrine a novel option for PICD prevention in ACLF

Stroke up 30 percent since 2001 in HK’s ≤55-year-olds

Researchers from the University of Hong Kong (HKU) report that the incidence of “young stroke” (ie, strokes occurring in those aged 18–55 years) has increased by 30 percent in Hong Kong’s residents since 2001.

Stroke up 30 percent since 2001 in HK’s ≤55-year-olds

05 Dec 2022

Smoking cessation intervention during lung screening may encourage quitting

A smoking cessation intervention, introduced as part of lung health screening, may encourage quitting in about 30 percent of smokers, results of the UK-based YESS* trial showed.

Smoking cessation intervention during lung screening may encourage quitting

Anti-Xa levels useful for therapy safety, drug concentration assessment

Monitoring of anti-Xa levels appears beneficial in evaluating current drug concentrations, ensuring immediate safety of therapy, and guiding possible clinical interventions, according to a study.

Anti-Xa levels useful for therapy safety, drug concentration assessment

Dose reduction needed in HFrEF patients on sacubitril-valsartan

Some patients with heart failure with reduced ejection fraction (HFrEF) need a loop diuretic dose reduction within 2‒3 months following initiation of sacubitril-valsartan, suggests a study.

Dose reduction needed in HFrEF patients on sacubitril-valsartan

05 Dec 2022

Pembrolizumab a novel treatment alternative for early-stage NSCLC?

In the second interim analysis of the PEARLS/KEYNOTE-091 study, adjuvant pembrolizumab monotherapy provided a clinically meaningful improvement in disease-free survival (DFS) in individuals with stage IB–IIIA non-small cell lung cancer (NSCLC) after complete resection and adjuvant chemotherapy (CT).

Pembrolizumab a novel treatment alternative for early-stage NSCLC?

Dip in serum cholesterol tied to higher pancreatic cancer risk